Neumora Therapeutics (NMRA) Operating Income (2022 - 2026)

Neumora Therapeutics' Operating Income history runs 5 years deep, the most recent figure standing at -$52.9 million for Q1 2026.

• In Q1 2026, Operating Income rose 25.48% year-over-year to -$52.9 million; the TTM figure through Mar 2026 stood at -$223.1 million (up 18.68% YoY), while the FY2025 annual figure was -$241.2 million, up 8.47% from the prior year.
• Operating Income for Q1 2026 stood at -$52.9 million, up from -$58.5 million in the prior quarter.
• The five-year high for Operating Income was -$30.6 million in Q3 2022, with the low at -$114.0 million in Q4 2023.
• The 5-year median for Operating Income is -$57.7 million (2025), against an average of -$58.1 million.
• The sharpest annual moves came in 2023 and 2024: Operating Income plunged 271.13% in 2023, then surged 44.81% in 2024.
• Neumora Therapeutics' Operating Income stood at -$30.7 million in 2022, then slumped by 271.13% to -$114.0 million in 2023, then soared by 44.81% to -$62.9 million in 2024, then advanced by 7.06% to -$58.5 million in 2025, then increased by 9.6% to -$52.9 million in 2026.
• Business Quant data shows NMRA's Operating Income at -$52.9 million in Q1 2026, -$58.5 million in Q4 2025, and -$57.7 million in Q3 2025.